Engineering chimeric antigen receptor CD4 T cells for Alzheimer's disease

Area of Science:

• Neuroimmunology
• Cellular Therapy
• Neurodegenerative Diseases

Background:

• Alzheimer's disease (AD) is a leading cause of dementia, with current antibody immunotherapies offering limited cognitive benefits and potential risks.
• Emerging evidence implicates T cells in AD pathogenesis, with CD4+ T cells showing potential for inflammation regulation and improved outcomes in AD models.

Purpose of the Study:

• To develop a universal therapeutic approach for AD by engineering CD4+ T cells with chimeric antigen receptors (CARs).
• To target fibrillar forms of aggregated amyloid-beta (Aβ) to reduce AD pathology and improve cognitive function.

Main Methods:

• Engineering CD4+ T cells with CARs specific for fibrillar Aβ.
• Evaluating the efficacy of CAR-T cells in altering amyloid deposition and brain pathology in AD models.
• Assessing the impact of CAR-T treatment on endogenous immune cell populations within the central nervous system (CNS).

Main Results:

• Optimized CAR-T cells demonstrated the ability to modify amyloid deposition in the dura and decrease parenchymal brain pathology.
• CAR-T treatment stimulated the expansion and recruitment of endogenous CD4+ T cells into the brain and leptomeninges.
• Amyloid plaque-specific CAR-T cells proved feasible as a potential therapeutic strategy for AD.

Conclusions:

• CD4+ CAR-T cell therapy represents a viable therapeutic avenue for AD, potentially modifying amyloid pathology.
• This approach may reshape the CNS immune landscape, offering a new direction for cellular immunotherapies in neurodegenerative diseases.